Hendry Lawrence B, Mahesh Virendra B, Bransome Edwin D, Ewing Douglas E
Accelerated Pharmaceuticals Inc., Augusta, GA, United States.
Mutat Res. 2007 Oct 1;623(1-2):53-71. doi: 10.1016/j.mrfmmm.2007.03.009. Epub 2007 Mar 24.
The binding of small molecules to double stranded DNA including intercalation between base pairs has been a topic of research for over 40 years. For the most part, however, intercalation has been of marginal interest given the prevailing notion that binding of small molecules to protein receptors is largely responsible for governing biological function. This picture is now changing with the discovery of nuclear enzymes, e.g. topoisomerases that modulate intercalation of various compounds including certain antitumor drugs and genotoxins. While intercalators are classically flat, aromatic structures that can easily insert between base pairs, our laboratories reported in 1977 that a number of biologically active compounds with greater molecular thickness, e.g. steroid hormones, could fit stereospecifically between base pairs. The hypothesis was advanced that intercalation was a salient feature of the action of gene regulatory molecules. Two parallel lines of research were pursued: (1) development of technology to employ intercalation in the design of safe and effective chemicals, e.g. pharmaceuticals, nutraceuticals, agricultural chemicals; (2) exploration of intercalation in the mode of action of nuclear receptor proteins. Computer modeling demonstrated that degree of fit of certain small molecules into DNA intercalation sites correlated with degree of biological activity but not with strength of receptor binding. These findings led to computational tools including pharmacophores and search engines to design new drug candidates by predicting desirable and undesirable activities. The specific sequences in DNA into which ligands best intercalated were later found in the consensus sequences of genes activated by nuclear receptors implying intercalation was central to their mode of action. Recently, the orientation of ligands bound to nuclear receptors was found to match closely the spatial locations of ligands derived from intercalation into unwound gene sequences suggesting that nuclear receptors may be guiding ligands to DNA with remarkable precision. Based upon multiple lines of experimental evidence, we suggest that intercalation in double stranded DNA is a ubiquitous, natural process and a salient feature of the regulation of genes. If double stranded DNA is proven to be the ultimate target of genomic drug action, intercalation will emerge as a cornerstone of the future discovery of safe and effective pharmaceuticals.
小分子与双链DNA的结合,包括在碱基对之间的嵌入,已经是40多年来的研究课题。然而,在很大程度上,鉴于普遍认为小分子与蛋白质受体的结合在很大程度上决定生物功能,嵌入一直未受到太多关注。随着核酶的发现,这种情况正在改变,例如拓扑异构酶可调节包括某些抗肿瘤药物和基因毒素在内的各种化合物的嵌入。虽然嵌入剂通常是扁平的芳香结构,能够轻松插入碱基对之间,但我们实验室在1977年报告称,一些分子厚度更大的生物活性化合物,如甾体激素,也能立体特异性地嵌入碱基对之间。于是提出了这样的假说:嵌入是基因调控分子作用的一个显著特征。我们开展了两条平行的研究路线:(1)开发在安全有效化学品(如药物、营养保健品、农用化学品)设计中利用嵌入作用的技术;(2)探索嵌入作用在核受体蛋白作用模式中的情况。计算机建模表明,某些小分子与DNA嵌入位点的契合程度与生物活性程度相关,而与受体结合强度无关。这些发现催生了包括药效基团和搜索引擎在内的计算工具,用于通过预测期望和不期望的活性来设计新的候选药物。后来发现,配体最易嵌入的DNA特定序列存在于核受体激活的基因的共有序列中,这意味着嵌入是其作用模式的核心。最近发现,与核受体结合的配体的取向与嵌入解开的基因序列中的配体的空间位置密切匹配,这表明核受体可能以极高的精度引导配体与DNA结合。基于多条实验证据,我们认为双链DNA中的嵌入是一个普遍存在的自然过程,也是基因调控的一个显著特征。如果双链DNA被证明是基因组药物作用的最终靶点,那么嵌入将成为未来安全有效药物发现的基石。